Determination of Regulatory Review Period for Purposes of Patent Extension; AMPYRA

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for the patent extension of AMPYRA, a human drug product, following the submission of patent extension applications to the Director of Patents and Trademarks, Department of Commerce. The FDA is publishing this notice as required by law.